IMR Press / EJGO / Volume 26 / Issue 4 / pii/2005193

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research

The activity of cancer procoagulant in cases of uterine leiomyomas

Show Less
1 Department of Gynecology, Medical University of Bialystok, Bialystok (Poland)
2 Laboratory of Clinical Analysis, Medical University of Bialystok, Bialystok (Poland)
3 Department of Clinical Pathology, Medical University of Bialystok, Bialystok (Poland)
Eur. J. Gynaecol. Oncol. 2005, 26(4), 407–410;
Published: 10 August 2005
Abstract

Purpose: It is currently believed that cancer procoagulant (CP), an enzymatic protein, is a product of malignant neoplastic cells. The present study was designed to test whether it is also synthesized by benign neoplastic cells, namely uterine leiomyomas. Materials and methods: We determined the activity of CP in the blood serum of women with uterine leiomyomas (N = 24), normal women (N = 15), and genital cancer patients (N = 6) by the coagulative method according to Gordon and Benson. Also, the CP activity in 10% tissue homogenates of uterine leiomyomas, normal uterine muscle and tissues of cervical and endometrial carcinoma was determined by the chromogenic method according to Colucci et al. Results: The mean CP activity in the sera of women with uterine leiomyomas was 181.1 seconds (s) ± 19.9 s, in healthy women - 293.2 s ± 33.8 s, and in genital cancer patients - 78.8 ± 18.5 s (all differences: p < 0.001). Similarly, in homogenates of uterine leiomyomas the CP activity was 19.6 ± 3.8 nmoles pN小ml, in normal uterine muscle it was 13.2 ± 2.2 nmoles pNa/ml, and in can­cerous tissue - 28.0 ± 6.6 nmol pNa/ml (all values being significantly different from each other). There was a strong correlation (r = -0.8122; p < 0.001) between the CP activity in uterine leiomyomas and serum activity, suggesting that the source of the serum CP activity was from the leiomyoma. The coagulation time of 120 to 240 s by the Gordon and Benson method supported the diag­nosis of uterine leiomyoma, and a value below 120 s - the suspicion of genital cancer. Conclusions: Uterine leiomyomas, representing benign genital neoplasia, synthesize CP and are the likely origin of CP activity in blood, as has been described for malignant tumors, but to a lesser degree. There may be a role for CP as a tumor marker of genital neoplasia.

Keywords
Cancer procoagulant
Clotting system
Uterine leiomyomas
Share
Back to top